Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Lung protein appears to play a key role in smoking-related emphysema

An international research team has identified a lung protein that appears to play a key role in smoking-related emphysema and have crafted an antibody to block its activity, Indiana University scientists reported.

17 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

New A+PSA assay more accurately detects prostate cancer

A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 May 2011

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.

17 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Study evaluates link between thyroid autoantibodies, miscarriage and preterm birth

GW Researcher Dr. Alex Stagnaro-Green, and colleagues, have contributed an editorial featured in the May 14 issue of the British Medical Journal reviewing a study that evaluated the relationship between thyroid autoantibodies and both miscarriage and preterm birth.

11 May 2011

NTC, Aldevron partner to manufacture first plasmid DNA-based genetic cosmetic

Nature Technology Corporation "NTC" and Aldevron today announced a joint effort to manufacture the world's first plasmid DNA-based genetic cosmetic for Gene Facelift.

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

Donors' genetic profile affects graft survival after kidney transplantation

A new study by researchers at Wake Forest Baptist Medical Center sheds light on what causes certain kidneys to do better than others after being transplanted, providing doctors with an easy way to screen for donor kidneys that have the best chance of survival.

10 May 2011

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

VIMS develops new biosensor that can detect and track oil spills

A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.

6 May 2011

Antibody News and Research

Further Reading

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Lung protein appears to play a key role in smoking-related emphysema

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

New A+PSA assay more accurately detects prostate cancer

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Symphogen to present second-generation Sympress platform at ESACT conference

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Inovio first quarter total revenue increases to $3.1 million for 2011

Study evaluates link between thyroid autoantibodies, miscarriage and preterm birth

NTC, Aldevron partner to manufacture first plasmid DNA-based genetic cosmetic

Micromet first quarter total revenues decrease to $5.5 million

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Donors' genetic profile affects graft survival after kidney transplantation

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

VIMS develops new biosensor that can detect and track oil spills

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo